Global Opioid-Induced Constipation Market Insights and Forecast to 2027

Global Opioid-Induced Constipation Market Insights and Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Opioid-Induced Constipation Product Introduction
1.2 Market by Type
1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type
1.4.2 Methylnaltrexone Bromide
1.4.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Opioid-Induced Constipation Sales Estimates and Forecasts 2016-2027
2.2 Global Opioid-Induced Constipation Revenue Estimates and Forecasts 2016-2027
2.3 Global Opioid-Induced Constipation Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Opioid-Induced Constipation Regions by Sales
2.4.1 Global Top Opioid-Induced Constipation Regions by Sales (2016-2021)
2.4.2 Global Top Opioid-Induced Constipation Regions by Sales (2022-2027)
2.5 Global Top Opioid-Induced Constipation Regions by Revenue
2.5.1 Global Top Opioid-Induced Constipation Regions by Revenue (2016-2021)
2.5.2 Global Top Opioid-Induced Constipation Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Opioid-Induced Constipation Sales by Manufacturers
3.1.1 Global Top Opioid-Induced Constipation Manufacturers by Sales (2016-2021)
3.1.2 Global Top Opioid-Induced Constipation Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Opioid-Induced Constipation Sales in 2020
3.2 Global Opioid-Induced Constipation Revenue by Manufacturers
3.2.1 Global Top Opioid-Induced Constipation Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Opioid-Induced Constipation Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Opioid-Induced Constipation Revenue in 2020
3.3 Global Opioid-Induced Constipation Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Opioid-Induced Constipation Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Opioid-Induced Constipation Sales by Type
4.1.1 Global Opioid-Induced Constipation Historical Sales by Type (2016-2021)
4.1.2 Global Opioid-Induced Constipation Forecasted Sales by Type (2022-2027)
4.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
4.2 Global Opioid-Induced Constipation Revenue by Type
4.2.1 Global Opioid-Induced Constipation Historical Revenue by Type (2016-2021)
4.2.2 Global Opioid-Induced Constipation Forecasted Revenue by Type (2022-2027)
4.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
4.3 Global Opioid-Induced Constipation Price by Type
4.3.1 Global Opioid-Induced Constipation Price by Type (2016-2021)
4.3.2 Global Opioid-Induced Constipation Price Forecast by Type (2022-2027)
5 Market Size by Application
5.1 Global Opioid-Induced Constipation Sales by Application
5.1.1 Global Opioid-Induced Constipation Historical Sales by Application (2016-2021)
5.1.2 Global Opioid-Induced Constipation Forecasted Sales by Application (2022-2027)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
5.2 Global Opioid-Induced Constipation Revenue by Application
5.2.1 Global Opioid-Induced Constipation Historical Revenue by Application (2016-2021)
5.2.2 Global Opioid-Induced Constipation Forecasted Revenue by Application (2022-2027)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
5.3 Global Opioid-Induced Constipation Price by Application
5.3.1 Global Opioid-Induced Constipation Price by Application (2016-2021)
5.3.2 Global Opioid-Induced Constipation Price Forecast by Application (2022-2027)
6 North America
6.1 North America Opioid-Induced Constipation Market Size by Type
6.1.1 North America Opioid-Induced Constipation Sales by Type (2016-2027)
6.1.2 North America Opioid-Induced Constipation Revenue by Type (2016-2027)
6.2 North America Opioid-Induced Constipation Market Size by Application
6.2.1 North America Opioid-Induced Constipation Sales by Application (2016-2027)
6.2.2 North America Opioid-Induced Constipation Revenue by Application (2016-2027)
6.3 North America Opioid-Induced Constipation Market Size by Country
6.3.1 North America Opioid-Induced Constipation Sales by Country (2016-2027)
6.3.2 North America Opioid-Induced Constipation Revenue by Country (2016-2027)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Opioid-Induced Constipation Market Size by Type
7.1.1 Europe Opioid-Induced Constipation Sales by Type (2017-2027)
7.1.2 Europe Opioid-Induced Constipation Revenue by Type (2017-2027)
7.2 Europe Opioid-Induced Constipation Market Size by Application
7.2.1 Europe Opioid-Induced Constipation Sales by Application (2017-2027)
7.2.2 Europe Opioid-Induced Constipation Revenue by Application (2017-2027)
7.3 Europe Opioid-Induced Constipation Market Size by Country
7.3.1 Europe Opioid-Induced Constipation Sales by Country (2017-2027)
7.3.2 Europe Opioid-Induced Constipation Revenue by Country (2017-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Opioid-Induced Constipation Market Size by Type
8.1.1 Asia Pacific Opioid-Induced Constipation Sales by Type (2018-2027)
8.1.2 Asia Pacific Opioid-Induced Constipation Revenue by Type (2018-2027)
8.2 Asia Pacific Opioid-Induced Constipation Market Size by Application
8.2.1 Asia Pacific Opioid-Induced Constipation Sales by Application (2018-2027)
8.2.2 Asia Pacific Opioid-Induced Constipation Revenue by Application (2018-2027)
8.3 Asia Pacific Opioid-Induced Constipation Market Size by Region
8.3.1 Asia Pacific Opioid-Induced Constipation Sales by Region (2018-2027)
8.3.2 Asia Pacific Opioid-Induced Constipation Revenue by Region (2018-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Opioid-Induced Constipation Market Size by Type
9.1.1 Latin America Opioid-Induced Constipation Sales by Type (2019-2027)
9.1.2 Latin America Opioid-Induced Constipation Revenue by Type (2019-2027)
9.2 Latin America Opioid-Induced Constipation Market Size by Application
9.2.1 Latin America Opioid-Induced Constipation Sales by Application (2019-2027)
9.2.2 Latin America Opioid-Induced Constipation Revenue by Application (2019-2027)
9.3 Latin America Opioid-Induced Constipation Market Size by Country
9.3.1 Latin America Opioid-Induced Constipation Sales by Country (2019-2027)
9.3.2 Latin America Opioid-Induced Constipation Revenue by Country (2019-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
6 Middle East and Africa
6.1 Middle East and Africa Opioid-Induced Constipation Market Size by Type
6.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Type (2016-2027)
6.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Type (2016-2027)
6.2 Middle East and Africa Opioid-Induced Constipation Market Size by Application
6.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Application (2016-2027)
6.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Application (2016-2027)
6.3 Middle East and Africa Opioid-Induced Constipation Market Size by Country
6.3.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2027)
6.3.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2027)
6.3.3 Turkey
6.3.4 Saudi Arabia
6.3.5 U.A.E
11 Company Profiles
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Overview
11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Description
11.1.5 Takeda Pharmaceuticals Related Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Overview
11.2.3 Bayer Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Bayer Opioid-Induced Constipation Product Description
11.2.5 Bayer Related Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Sanofi Opioid-Induced Constipation Product Description
11.3.5 Sanofi Related Developments
11.4 Mallinckrodt
11.4.1 Mallinckrodt Corporation Information
11.4.2 Mallinckrodt Overview
11.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Mallinckrodt Opioid-Induced Constipation Product Description
11.4.5 Mallinckrodt Related Developments
11.5 Salix (Bausch Health)
11.5.1 Salix (Bausch Health) Corporation Information
11.5.2 Salix (Bausch Health) Overview
11.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Description
11.5.5 Salix (Bausch Health) Related Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 AstraZeneca Opioid-Induced Constipation Product Description
11.6.5 AstraZeneca Related Developments
11.7 Progenics Pharmaceuticals
11.7.1 Progenics Pharmaceuticals Corporation Information
11.7.2 Progenics Pharmaceuticals Overview
11.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Description
11.7.5 Progenics Pharmaceuticals Related Developments
11.8 Purdue Pharm
11.8.1 Purdue Pharm Corporation Information
11.8.2 Purdue Pharm Overview
11.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Purdue Pharm Opioid-Induced Constipation Product Description
11.8.5 Purdue Pharm Related Developments
11.9 Nektar Therapeutics
11.9.1 Nektar Therapeutics Corporation Information
11.9.2 Nektar Therapeutics Overview
11.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Description
11.9.5 Nektar Therapeutics Related Developments
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Corporation Information
11.10.2 Daiichi Sankyo Overview
11.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Description
11.10.5 Daiichi Sankyo Related Developments
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Overview
11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Description
11.1.5 Takeda Pharmaceuticals Related Developments
11.12 GSK
11.12.1 GSK Corporation Information
11.12.2 GSK Overview
11.12.3 GSK Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.12.4 GSK Product Description
11.12.5 GSK Related Developments
11.13 Shionogi
11.13.1 Shionogi Corporation Information
11.13.2 Shionogi Overview
11.13.3 Shionogi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.13.4 Shionogi Product Description
11.13.5 Shionogi Related Developments
12 Value Chain and Sales Channels Analysis
12.1 Opioid-Induced Constipation Value Chain Analysis
12.2 Opioid-Induced Constipation Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid-Induced Constipation Production Mode & Process
12.4 Opioid-Induced Constipation Sales and Marketing
12.4.1 Opioid-Induced Constipation Sales Channels
12.4.2 Opioid-Induced Constipation Distributors
12.5 Opioid-Induced Constipation Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Opioid-Induced Constipation Industry Trends
13.2 Opioid-Induced Constipation Market Drivers
13.3 Opioid-Induced Constipation Market Challenges
13.4 Opioid-Induced Constipation Market Restraints
14 Key Findings in The Global Opioid-Induced Constipation Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Methylnaltrexone Bromide
Table 3. Major Manufacturers of Lubiprostone
Table 4. Major Manufacturers of Naloxegol
Table 5. Major Manufacturers of Others
Table 6. Global Opioid-Induced Constipation Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Opioid-Induced Constipation Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 8. Global Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 9. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 10. Global Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 11. Global Opioid-Induced Constipation Sales Market Share by Region (2022-2027)
Table 12. Global Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
Table 13. Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
Table 14. Global Opioid-Induced Constipation Revenue by Region (2022-2027) & (US$ Million)
Table 15. Global Opioid-Induced Constipation Revenue Market Share by Region (2022-2027)
Table 16. Global Opioid-Induced Constipation Sales by Manufacturers (2016-2021) & (K Units)
Table 17. Global Opioid-Induced Constipation Sales Share by Manufacturers (2016-2021)
Table 18. Global Opioid-Induced Constipation Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 19. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2016-2021)
Table 20. Opioid-Induced Constipation Price by Manufacturers 2016-2021 (USD/Unit)
Table 21. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2020)
Table 23. Opioid-Induced Constipation Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Opioid-Induced Constipation Product Offered
Table 25. Date of Manufacturers Enter into Opioid-Induced Constipation Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 28. Global Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 29. Global Opioid-Induced Constipation Sales Share by Type (2016-2021)
Table 30. Global Opioid-Induced Constipation Sales Share by Type (2022-2027)
Table 31. Global Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 32. Global Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 33. Global Opioid-Induced Constipation Revenue Share by Type (2016-2021)
Table 34. Global Opioid-Induced Constipation Revenue Share by Type (2022-2027)
Table 35. Opioid-Induced Constipation Price by Type (2016-2021) & (USD/Unit)
Table 36. Global Opioid-Induced Constipation Price Forecast by Type (2022-2027) & (USD/Unit)
Table 37. Global Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 38. Global Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 39. Global Opioid-Induced Constipation Sales Share by Application (2016-2021)
Table 40. Global Opioid-Induced Constipation Sales Share by Application (2022-2027)
Table 41. Global Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 42. Global Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 43. Global Opioid-Induced Constipation Revenue Share by Application (2016-2021)
Table 44. Global Opioid-Induced Constipation Revenue Share by Application (2022-2027)
Table 45. Opioid-Induced Constipation Price by Application (2016-2021) & (USD/Unit)
Table 46. Global Opioid-Induced Constipation Price Forecast by Application (2022-2027) & (USD/Unit)
Table 47. North America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 48. North America Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 49. North America Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 50. North America Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 51. North America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 52. North America Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 53. North America Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 54. North America Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 55. North America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 56. North America Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 57. North America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 58. North America Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 59. Europe Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 60. Europe Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 61. Europe Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 62. Europe Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 63. Europe Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 64. Europe Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 65. Europe Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 66. Europe Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 67. Europe Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 68. Europe Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 69. Europe Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 70. Europe Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 71. Asia Pacific Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 72. Asia Pacific Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 73. Asia Pacific Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 74. Asia Pacific Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 75. Asia Pacific Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 76. Asia Pacific Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 77. Asia Pacific Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 78. Asia Pacific Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 79. Asia Pacific Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 80. Asia Pacific Opioid-Induced Constipation Sales by Region (2022-2027) & (K Units)
Table 81. Asia Pacific Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
Table 82. Asia Pacific Opioid-Induced Constipation Revenue by Region (2022-2027) & (US$ Million)
Table 83. Latin America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 84. Latin America Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 85. Latin America Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 86. Latin America Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 87. Latin America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 88. Latin America Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 89. Latin America Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 90. Latin America Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 91. Latin America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 92. Latin America Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 93. Latin America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 94. Latin America Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 95. Middle East and Africa Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 96. Middle East and Africa Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 97. Middle East and Africa Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 98. Middle East and Africa Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 99. Middle East and Africa Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 100. Middle East and Africa Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 101. Middle East and Africa Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 102. Middle East and Africa Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 103. Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 104. Middle East and Africa Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 105. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 106. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 107. Takeda Pharmaceuticals Corporation Information
Table 108. Takeda Pharmaceuticals Description and Major Businesses
Table 109. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 110. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 111. Takeda Pharmaceuticals Recent Developments
Table 112. Bayer Corporation Information
Table 113. Bayer Description and Major Businesses
Table 114. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 115. Bayer Opioid-Induced Constipation Product
Table 116. Bayer Recent Developments
Table 117. Sanofi Corporation Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 120. Sanofi Opioid-Induced Constipation Product
Table 121. Sanofi Recent Developments
Table 122. Mallinckrodt Corporation Information
Table 123. Mallinckrodt Description and Major Businesses
Table 124. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 125. Mallinckrodt Opioid-Induced Constipation Product
Table 126. Mallinckrodt Recent Developments
Table 127. Salix (Bausch Health) Corporation Information
Table 128. Salix (Bausch Health) Description and Major Businesses
Table 129. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 130. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 131. Salix (Bausch Health) Recent Developments
Table 132. AstraZeneca Corporation Information
Table 133. AstraZeneca Description and Major Businesses
Table 134. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 135. AstraZeneca Opioid-Induced Constipation Product
Table 136. AstraZeneca Recent Developments
Table 137. Progenics Pharmaceuticals Corporation Information
Table 138. Progenics Pharmaceuticals Description and Major Businesses
Table 139. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 140. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 141. Progenics Pharmaceuticals Recent Developments
Table 142. Purdue Pharm Corporation Information
Table 143. Purdue Pharm Description and Major Businesses
Table 144. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 145. Purdue Pharm Opioid-Induced Constipation Product
Table 146. Purdue Pharm Recent Developments
Table 147. Nektar Therapeutics Corporation Information
Table 148. Nektar Therapeutics Description and Major Businesses
Table 149. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 150. Nektar Therapeutics Opioid-Induced Constipation Product
Table 151. Nektar Therapeutics Recent Developments
Table 152. Daiichi Sankyo Corporation Information
Table 153. Daiichi Sankyo Description and Major Businesses
Table 154. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 155. Daiichi Sankyo Opioid-Induced Constipation Product
Table 156. Daiichi Sankyo Recent Developments
Table 157. Prestige Corporation Information
Table 158. Prestige Description and Major Businesses
Table 159. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 160. Prestige Opioid-Induced Constipation Product
Table 161. Prestige Recent Developments
Table 162. GSK Corporation Information
Table 163. GSK Description and Major Businesses
Table 164. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 165. GSK Opioid-Induced Constipation Product
Table 166. GSK Recent Developments
Table 167. Shionogi Corporation Information
Table 168. Shionogi Description and Major Businesses
Table 169. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 170. Shionogi Opioid-Induced Constipation Product
Table 171. Shionogi Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Opioid-Induced Constipation Distributors List
Table 175. Opioid-Induced Constipation Customers List
Table 176. Opioid-Induced Constipation Market Trends
Table 177. Opioid-Induced Constipation Market Drivers
Table 178. Opioid-Induced Constipation Market Challenges
Table 179. Opioid-Induced Constipation Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid-Induced Constipation Product Picture
Figure 2. Global Opioid-Induced Constipation Market Share by Type in 2020 & 2027
Figure 3. Methylnaltrexone Bromide Product Picture
Figure 4. Lubiprostone Product Picture
Figure 5. Naloxegol Product Picture
Figure 6. Others Product Picture
Figure 7. Global Opioid-Induced Constipation Sales Market Share by Application in 2020 & 2027
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Opioid-Induced Constipation Report Years Considered
Figure 11. Global Opioid-Induced Constipation Sales 2016-2027 (K Units)
Figure 12. Global Opioid-Induced Constipation Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Opioid-Induced Constipation Revenue 2016-2027 (US$ Million)
Figure 14. Global Opioid-Induced Constipation Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 15. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Figure 16. Global Opioid-Induced Constipation Sales Market Share by Region (2022-2027)
Figure 17. North America Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 18. North America Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Europe Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 20. Europe Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Asia-Pacific Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 22. Asia-Pacific Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Latin America Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 24. Latin America Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 25. Middle East & Africa Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 26. Middle East & Africa Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Opioid-Induced Constipation Sales in 2020
Figure 28. The Top 10 and Top 5 Players Market Share by Opioid-Induced Constipation Revenue in 2020
Figure 29. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 30. Global Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 3

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87

The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......

Global Esomeprazole Magnesium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......

Global Combination Therapy Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......

Global Axitinib Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68

The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......

Global Lyme Disease Vaccine Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70

The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......

Global Transdermal Absorption Patch Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......

Global Ketoprofen Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......

Global Methyl Salicylate Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82

The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......

Global Diclofenac Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs